Top-News
Dienstag,
08.11.2016 22:10
von
PR Newswire
| Aufrufe: 20
Jazz Pharmaceuticals Announces Third Quarter 2016 Financial Results
Eine Wissenschaftlerin bei einer Untersuchung. (Symbolbild)
© Stas_Uvarov / iStock / Getty Images Plus / Getty Images
http://www.gettyimages.de/
PR Newswire
DUBLIN, Nov. 8, 2016
DUBLIN, Nov. 8, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2016 and updated financial guidance for 2016.
"We have made substantial progress towards achieving our corporate objectives for 2016, delivering solid top-line growth in our commercial business, investing in broadening our hematology/oncology portfolio with the completion of the Celator acquisition and increasing our investments in R&D," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "In the third quarter, we began a rolling NDA submission for Vyxeos for the treatment of acute myeloid leukemia, and we are pleased with the achievement of important clinical milestones, advancement of key R&D programs and expansion of our clinical development portfolio, all of which support our goal of developing and commercializing meaningful therapies for patients while building shareholder value."
GAAP net income attributable to Jazz Pharmaceuticals plc for the third quarter of 2016 was $87.1 million, or $1.41 per diluted share, compared to $88.0 million, or $1.39 per diluted share, for the third quarter of 2015.
Adjusted net income attributable to Jazz Pharmaceuticals plc for the third quarter of 2016 was $158.5 million, or $2.57 per diluted share, compared to $159.3 million, or $2.52 per diluted share, for the third quarter of 2015. Reconciliations of applicable GAAP reported to non-GAAP adjusted information are included in this press release.
| Financial Highlights | |||||||||||||||||||||||||||||||
| | |||||||||||||||||||||||||||||||
| | Three Months Ended ARIVA.DE Börsen-GeflüsterWerbung Weiter aufwärts?
 Morgan Stanley
Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie hier: ME2X7G,. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Kurse
| | | | Nine Months Ended | | | ||||||||||||||||||||||||
| (In thousands, except per share amounts and percentages) | 2016 | | 2015 | | Change | | 2016 | | 2015 | | Change | ||||||||||||||||||||
| Total revenues | $ | 374,181 | | | $ | 340,872 | | | 9.8 | % | | $ | 1,091,352 | | | $ | 983,922 | | | 10.9 | % | ||||||||||
| GAAP net income attributable to Jazz Pharmaceuticals plc | $ | 87,145 | | | $ | 87,960 | | | (0.9) | % | | $ | 272,548 | | | $ | 246,774 | | | 10.4 | % | ||||||||||
| Adjusted net income attributable to Jazz Pharmaceuticals plc1 | $ | 158,470 | | | $ | 159,302 | | | (0.5) | % | | $ | 453,931 | | | $ | 418,968 | | | 8.3 | % | ||||||||||
| GAAP EPS attributable to Jazz Pharmaceuticals plc | $ | 1.41 | | | $ | 1.39 | | | 1.4 | % | | $ | 4.40 | | | $ | 3.91 | | | 12.5 | % | ||||||||||
| Adjusted EPS attributable to Jazz Pharmaceuticals plc1 | $ | 2.57 | | | $ | 2.52 | | | 2.0 | % | | $ | 7.32 | | | $ | 6.64 | | | 10.2 | % | ||||||||||
| | | |||||
| | | | | | | |
| | | |||||
| 1. | Commencing with the second quarter of 2016, the company modified the calculation of its non-GAAP income tax provision in connection with the Securities and Exchange Commission's May 2016 guidance pertaining to non-GAAP financial measures. This modification is reflected in the company's 2015 and 2016 non-GAAP interim period results and full-year 2016 financial guidance. See "Non-GAAP Financial Measures" below. The modification did not have a material effect on the adjusted net income attributable to Jazz Pharmaceuticals plc or adjusted EPS for the three months ended September 30, 2015. The modification resulted in the reduction of adjusted net income attributable to Jazz Pharmaceuticals plc by $17.6 million, or $0.28 per diluted share, compared to the amount previously reported for the nine months ended September 30, 2015. | |||||
| Total Revenues | |||||||||||||||
| | |||||||||||||||
| | Three Months Ended | | Nine Months Ended | ||||||||||||
| (In thousands) | 2016 | | 2015 | | 2016 | | 2015 | ||||||||
| Xyrem® (sodium oxybate) oral solution | $ | 285,907 | | | $ | 242,899 | | | $ | 816,412 Werbung Mehr Nachrichten zur Jazz Pharmaceuticals Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1  Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News | |||||
